[go: up one dir, main page]

SG11201910101SA - Alphavirus neoantigen vectors - Google Patents

Alphavirus neoantigen vectors

Info

Publication number
SG11201910101SA
SG11201910101SA SG11201910101SA SG11201910101SA SG 11201910101S A SG11201910101S A SG 11201910101SA SG 11201910101S A SG11201910101S A SG 11201910101SA SG 11201910101S A SG11201910101S A SG 11201910101SA
Authority
SG
Singapore
Prior art keywords
gritstone
emeryville
oncology
international
suite
Prior art date
Application number
Inventor
Wade Blair
Karin Jooss
Amy Rappaport
Ciaran Scallan
Leonid Gitlin
Original Assignee
Gritstone Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gritstone Oncology Inc filed Critical Gritstone Oncology Inc
Publication of SG11201910101SA publication Critical patent/SG11201910101SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

Title: ALPHAVIRUS NEOANTIGEN VECTORS Patient 110 Candidate Neoanligen Sequences 114 Presentation Identification System 160 Presentation Information 165 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 15 November 2018 (15.11.2018) WIPO I PCT omit VIII °nolo Holollm iflo oimIE (10) International Publication Number WO 2018/208856 Al (51) International Patent Classification: A61K 35/76 (2015.01) CO7K 14/705 (2006.01) A61K 39/12 (2006.01) C12N 15/86 (2006.01) C07K 14/18 (2006.01) (21) International Application Number: PCT/US2018/031696 (22) International Filing Date: 08 May 2018 (08.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/503,283 08 May 2017 (08.05.2017) US 62/523,201 21 June 2017 (21.06.2017) US 62/590,163 22 November 2017 (22.11.2017) US (71) Applicant: GRITSTONE ONCOLOGY, INC. [US/US]; 5858 Horton Street, Suite 210, Emeryville, CA 94608 (US). (72) Inventors: BLAIR, Wade; Gritstone Oncology, Inc., 5858 Horton Street, Suite 210, Emeryville, CA 94608 (US). JOOSS, Karin; Gritstone Oncology, Inc., 5858 Horton Street, Suite 210, Emeryville, CA 94608 (US). RAPPA- PORT, Amy, Rachel; Gritstone Oncology, Inc., 5858 Horton Street, Suite 210, Emeryville, CA 94608 (US). SCALLAN, Ciaran, Daniel; Gritstone Oncology, Inc., 5858 Horton Street, Suite 210, Emeryville, CA 94608 (US). GITLIN, Leonid; Gritstone Oncology, Inc., 5858 Horton Street, Sutie 210, Emeryville, CA 94608 (US). (74) Agent: NEWMAN, Zachary, R. et al.; Fenwick & West LLP, 801 California Street, Mountain View, CA 94041 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Vaccine 118 1-1 00 FIG 2A 00 1-1 (57) : Disclosed herein are alphavirus vectors that include neoantigen-encoding nucleic acid sequences derived from a tumor © of a subject. Also disclosed are nucleotides, cells, and methods associated with the vectors including their use as vaccines. C [Continued on next page] WO 2018/208856 Al MIDEDIMOMMIDEFIEHIMIIMMERIMODEVOIS Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3))
SG11201910101S 2017-05-08 2018-05-08 Alphavirus neoantigen vectors SG11201910101SA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762503283P 2017-05-08 2017-05-08
US201762523201P 2017-06-21 2017-06-21
US201762590163P 2017-11-22 2017-11-22
PCT/US2018/031696 WO2018208856A1 (en) 2017-05-08 2018-05-08 Alphavirus neoantigen vectors

Publications (1)

Publication Number Publication Date
SG11201910101SA true SG11201910101SA (en) 2019-11-28

Family

ID=64105513

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201910101S SG11201910101SA (en) 2017-05-08 2018-05-08 Alphavirus neoantigen vectors

Country Status (17)

Country Link
US (4) US11504421B2 (en)
EP (1) EP3634449A4 (en)
JP (2) JP2020518648A (en)
KR (1) KR20200003390A (en)
CN (1) CN110612116A (en)
AU (2) AU2018266705B2 (en)
BR (1) BR112019023477A2 (en)
CA (1) CA3062591A1 (en)
CO (1) CO2019013609A2 (en)
IL (2) IL270396B2 (en)
MX (2) MX2019013259A (en)
PE (1) PE20191842A1 (en)
PH (1) PH12019502518A1 (en)
SG (1) SG11201910101SA (en)
TW (2) TW201907937A (en)
WO (1) WO2018208856A1 (en)
ZA (1) ZA201907461B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110545810A (en) * 2016-11-23 2019-12-06 磨石肿瘤生物技术公司 Viral delivery of neoantigens
KR102565256B1 (en) 2017-02-12 2023-08-08 바이오엔테크 유에스 인크. HLA-Based Methods and Compositions and Their Uses
SG11201910101SA (en) 2017-05-08 2019-11-28 Gritstone Oncology Inc Alphavirus neoantigen vectors
GB201812474D0 (en) 2018-07-31 2018-09-12 Autolus Ltd Nucleic acid construct
WO2020072371A1 (en) * 2018-10-01 2020-04-09 The Wistar Institute Melanoma canine vaccine compositions and methods of use thereof
CN109536464B (en) * 2018-12-10 2022-06-10 中国科学院武汉病毒研究所 Chikungunya virus infectious clone with deletion of capsid protein gene, construction method and application in preparation of attenuated vaccine
EP3893927A1 (en) * 2018-12-14 2021-10-20 GlaxoSmithKline Biologicals S.A. Heterologous prime boost vaccine compositions and methods
TWI852977B (en) 2019-01-10 2024-08-21 美商健生生物科技公司 Prostate neoantigens and their uses
BR112021024127A2 (en) 2019-05-30 2022-04-26 Gritstone Bio Inc modified adenovirus
CA3141084A1 (en) * 2019-06-12 2020-12-17 Vikram JUNEJA Neoantigen compositions and uses thereof
WO2021003348A1 (en) * 2019-07-02 2021-01-07 Gritstone Oncology, Inc. Hiv antigens and mhc complexes
CA3145791A1 (en) 2019-07-16 2021-01-21 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
CN110515301B (en) * 2019-08-06 2021-06-08 大连理工大学 Improved ADMM algorithm combined with DMPC
CN114761555A (en) 2019-08-09 2022-07-15 胡桃钳医疗公司 Manufacturing method and apparatus for removing material from therapeutic compositions
WO2021092095A1 (en) * 2019-11-04 2021-05-14 Gritstone Oncology, Inc. Neoantigen vaccine therapy
CR20220220A (en) 2019-11-18 2022-09-20 Janssen Biotech Inc VACCINES BASED ON CALR AND JAK2 MUTANTS AND THEIR USES
WO2021183564A1 (en) 2020-03-09 2021-09-16 Arcturus Therapeutics, Inc. Compositions and methods for inducing immune responses
CN115942942A (en) * 2020-04-03 2023-04-07 磨石生物公司 Infectious Disease Antigens and Vaccines
JP2023523414A (en) * 2020-04-21 2023-06-05 グリットストーン バイオ インコーポレイテッド Capping compounds, compositions, and methods of use
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
CN111951887B (en) * 2020-07-27 2024-06-28 深圳市新合生物医疗科技有限公司 Leucocyte antigen and polypeptide binding affinity prediction method based on deep learning
WO2022032196A2 (en) * 2020-08-06 2022-02-10 Gritstone Bio, Inc. Multiepitope vaccine cassettes
IL300519A (en) 2020-08-14 2023-04-01 Arcturus Therapeutics Inc Method of lyophilizing lipid nanoparticles
CN114438128A (en) * 2020-10-30 2022-05-06 上海市公共卫生临床中心 An enhanced oncolytic adenovirus and its application
AU2021385572A1 (en) 2020-11-25 2023-06-22 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids, and related methods of use
US12275766B2 (en) 2020-12-23 2025-04-15 Janssen Biotech, Inc. Neoantigen peptide mimics
CN112553232B (en) * 2020-12-29 2022-10-21 中国科学院武汉病毒研究所 Controllable biosynthesis method of multifunctional self-assembled nanoparticles
JP7693813B2 (en) 2021-01-14 2025-06-17 ギリアード サイエンシーズ， インコーポレイテッド HIV vaccines and methods of use
WO2022159511A2 (en) * 2021-01-19 2022-07-28 Gritstone Bio, Inc. Modified alphavirus vectors
IL319926A (en) * 2021-03-19 2025-05-01 Tiba Biotech Llc Artificial alphavirus-derived rna repliconexpression systems
WO2022229966A1 (en) 2021-04-29 2022-11-03 Yeda Research And Development Co. Ltd. T cell receptors directed against ras-derived recurrent neoantigens and methods of identifying same
CN113517030B (en) * 2021-07-19 2022-09-20 中国人民解放军国防科技大学 Gene sequence representation learning method based on virus propagation network
US20230050657A1 (en) * 2021-07-22 2023-02-16 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Single Domain Antibodies that Bind and Neutralize Venezuelan Equine Encephalitis Virus
EP4401760A1 (en) * 2021-09-13 2024-07-24 OncoDNA Method to generate personalized neoantigens of a tumor of a patient
WO2023172633A1 (en) * 2022-03-08 2023-09-14 Avalo, Inc. System and method for genomic association
EP4496584A2 (en) * 2022-03-21 2025-01-29 Gritstone bio, Inc. Low-dose neoantigen vaccine therapy
WO2023230587A2 (en) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
WO2024026274A2 (en) * 2022-07-26 2024-02-01 Yale University Virus-like vesicles (vlvs) based vaccines and methods of preventing, ameliorating, and/or treating covid-19 and/or hepatocellular carcinoma (hcc)
WO2025016031A1 (en) * 2023-07-19 2025-01-23 上海复诺健生物科技有限公司 Self-amplifying nucleic acid molecule and use thereof
WO2025106713A1 (en) * 2023-11-14 2025-05-22 Avalo, Inc. System and method for gene-environment analysis

Family Cites Families (229)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1837028A (en) 1924-11-11 1931-12-15 Om Edwards Co Inc Window construction
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5223427A (en) 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
FR2650840B1 (en) 1989-08-11 1991-11-29 Bertin & Cie RAPID DETECTION AND / OR IDENTIFICATION OF A SINGLE BASED ON A NUCLEIC ACID SEQUENCE, AND ITS APPLICATIONS
EP0452457B1 (en) 1989-11-03 1997-08-20 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US6770283B1 (en) 1990-12-13 2004-08-03 Bioption Ab DNA expression systems based on alphaviruses
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
US6037135A (en) 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
WO1993025673A1 (en) 1992-06-04 1993-12-23 The Regents Of The University Of California In vivo gene therapy with intron-free sequence of interest
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US20050271676A1 (en) 1993-03-05 2005-12-08 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
US6413935B1 (en) 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
WO1995007707A1 (en) 1993-09-14 1995-03-23 Cytel Corporation Alteration of immune response using pan dr-binding peptides
EP0814154B1 (en) 1993-09-15 2009-07-29 Novartis Vaccines and Diagnostics, Inc. Recombinant alphavirus vectors
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
JP3952312B2 (en) 1993-11-09 2007-08-01 メディカル カレッジ オブ オハイオ A stable cell line capable of expressing adeno-associated virus replication genes
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
FR2726285B1 (en) 1994-10-28 1996-11-29 Centre Nat Rech Scient ADENOVIRUSES CONTAINING VIABLE CONTAMINANT PARTICLES, PREPARATION AND USE
US6001557A (en) 1994-10-28 1999-12-14 The Trustees Of The University Of Pennsylvania Adenovirus and methods of use thereof
US5552350A (en) 1994-12-12 1996-09-03 Ceramco Inc. Low-fusing temperature porcelain
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5851796A (en) 1995-06-07 1998-12-22 Yale University Autoregulatory tetracycline-regulated system for inducible gene expression in eucaryotes
UY24367A1 (en) 1995-11-23 2000-10-31 Boehringer Ingelheim Int TUMOR VACCINES AND PRODUCTION PROCEDURE
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
EP0803573A1 (en) 1996-04-25 1997-10-29 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronic expression construct with cytokines for multivalent vaccines
US6514731B1 (en) 1996-05-24 2003-02-04 Chiron Corporation Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens
CA2259179C (en) 1996-07-03 2008-09-23 University Of Pittsburgh Emulsion formulations for hydrophilic active agents
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US5849561A (en) 1997-05-22 1998-12-15 Cornell Research Foundation, Inc. Method for the production of non-group C adenoviral vectors
ATE225400T1 (en) 1998-07-07 2002-10-15 Transgene Sa USE OF THE ADENOVIRAL E4 REGION READING FRAMEWORK TO IMPROVE GENE EXPRESSION
EP1000628A1 (en) 1998-09-28 2000-05-17 Fondation Mondiale Recherche et Prevention SIDA Use of antigenic complexes of HIV envelope and HLA class I antigens as HIV vaccine
US20030072767A1 (en) 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US20080050393A1 (en) 1998-12-03 2008-02-28 Tang Y Tom Novel nucleic acids and polypeptides
WO2000034445A2 (en) 1998-12-07 2000-06-15 U.S. Medical Research Institute Of Infectious Diseases Live attenuated venezuelan equine encephalitis vaccine
EP1150708A2 (en) 1999-02-11 2001-11-07 Genzyme Corporation Polynucleotide encoding multimers of antigenic peptides in order to enhance presentation of the antigenic peptide by mhc molecules
US7262049B2 (en) 1999-03-16 2007-08-28 Dana-Farber Cancer Institute, Inc. Pseudotyped lentiviral vectors and uses thereof
DE60038011T2 (en) 1999-04-08 2009-02-12 Novartis Vaccines and Diagnostics, Inc., Emeryville IMPROVEMENT OF THE IMMUNE RESPONSE AS APPLICATION IN VACCINATION AND GENE THERAPY
CA2373300C (en) 1999-04-14 2012-02-21 Chiron Corporation Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
WO2000073465A1 (en) 1999-05-28 2000-12-07 Ajinomoto Co.,Inc. Peptides capable of inducing hiv-specific ctl and preventives/remedies for aids containing the peptides
US6365394B1 (en) 1999-09-29 2002-04-02 The Trustees Of The University Of Pennsylvania Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus
CA2394741A1 (en) 1999-12-21 2001-06-28 Epimmune Inc. Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
CN1437476A (en) 1999-12-28 2003-08-20 埃皮缪纳股份有限公司 Optimized minigenes and peptides encoded thereby
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
US20040248113A1 (en) 1999-12-28 2004-12-09 Alessandro Sette Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby
EP1250351B1 (en) 2000-01-28 2005-11-30 Statens Serum Institut Methods to identify ctl epitopes of hiv
AU785151B2 (en) 2000-01-28 2006-10-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1
WO2001073027A2 (en) 2000-03-24 2001-10-04 Corixa Corporation Compositions and methods for therapy and diagnosis of colon cancer
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20040115625A1 (en) 2000-10-02 2004-06-17 Reinhard Ebner Cancer gene determination and therapeutic screening using signature gene sets
US6783939B2 (en) 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
AU2001291162A1 (en) 2000-09-25 2002-04-08 Regents Of The University Of Michigan Production of viral vectors
US20020137081A1 (en) 2001-01-08 2002-09-26 Olga Bandman Genes differentially expressed in vascular tissue activation
AU2002242016A1 (en) 2001-02-01 2002-08-12 The Johns Hopkins University Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
CN1147587C (en) 2001-05-30 2004-04-28 方炳良 Method of strengthening specific destination gene expression of cell
US20030232324A1 (en) 2001-05-31 2003-12-18 Chiron Corporation Chimeric alphavirus replicon particles
US7531180B2 (en) 2001-05-31 2009-05-12 Novartis Vaccines And Diagnostics, Inc Chimeric alphavirus replicon particles
WO2003000851A2 (en) 2001-06-22 2003-01-03 The Trustees Of The University Of Pennsylvania Method for rapid screening of bacterial transformants and novel simian adenovirus proteins
US20040136963A1 (en) 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
NZ534865A (en) 2002-04-25 2008-07-31 Crucell Holland Bv Stable adenoviral vectors and methods for propagation thereof
CN100497639C (en) 2002-04-25 2009-06-10 克鲁塞尔荷兰公司 Means and methods for the production of adenovirus vectors
WO2004023973A2 (en) 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics
EP1594447A2 (en) 2002-10-02 2005-11-16 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2500955A1 (en) 2002-10-03 2004-04-15 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
EP1590451B1 (en) 2002-12-13 2015-09-16 Alphavax, Inc. Alphavirus particles and methods for preparation
WO2004055166A2 (en) 2002-12-13 2004-07-01 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
GB2398300A (en) 2003-02-17 2004-08-18 Isis Innovation Method and compositions for boosting immune response
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
WO2005033265A2 (en) 2003-04-25 2005-04-14 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
CA2526146A1 (en) 2003-06-05 2005-02-24 Wyeth Holdings Corporation Immunogenic compositions comprising venezuelan equine encephalitis virus replicon vectors and paramyxovirus protein antigens
US7291498B2 (en) 2003-06-20 2007-11-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
DE10347710B4 (en) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Recombinant vaccines and their use
PL2163260T3 (en) 2004-01-23 2017-12-29 Msd Italia S.R.L. Chimpanzee adenovirus vaccine carriers
US8119336B2 (en) 2004-03-03 2012-02-21 Ibis Biosciences, Inc. Compositions for use in identification of alphaviruses
JP2007535550A (en) 2004-04-28 2007-12-06 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Continuous delivery of immunogenic molecules via adenovirus and adeno-associated virus mediated administration
WO2006033672A2 (en) 2004-04-28 2006-03-30 The Trustees Of The University Of Pennsylvania Immunization regimen with e4-deleted adenovirus prime and e1-deleted adenovirus boost
EP2811027A1 (en) 2004-05-21 2014-12-10 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for RSV and PIV vaccines
ES2526196T3 (en) 2004-05-25 2015-01-08 Novartis Vaccines And Diagnostics, Inc. Constructs of encapsidation of alphavirus replicons
US20060051405A1 (en) 2004-07-19 2006-03-09 Protiva Biotherapeutics, Inc. Compositions for the delivery of therapeutic agents and uses thereof
EP1797175B1 (en) 2004-10-04 2008-07-16 Biovaxim Limited Subtype-matched inactivated whole virus vaccines for treating patients with hiv infection
US20060198854A1 (en) 2004-12-28 2006-09-07 Peter Pushko Vector platforms derived from the alphavirus vaccines
US7220549B2 (en) 2004-12-30 2007-05-22 Helicos Biosciences Corporation Stabilizing a nucleic acid for nucleic acid sequencing
FR2882557A1 (en) 2005-02-25 2006-09-01 Centre Nat Rech Scient HIV EPITOPES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
US7283337B2 (en) 2005-03-04 2007-10-16 Headway Technologies, Inc. Abutted exchange bias design for sensor stabilization
SG162726A1 (en) * 2005-05-27 2010-07-29 San Raffaele Centro Fond Gene vector comprising mi-rna
EP4599852A2 (en) 2005-08-23 2025-08-13 The Trustees of the University of Pennsylvania Rna containing modified nucleosides and methods of use thereof
CA2626253A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
AU2007217352B2 (en) 2006-02-27 2013-09-26 The Board Of Regents Of The University Of Texas System Pseudoinfectious flavivirus and uses thereof
US20090022760A1 (en) 2006-09-12 2009-01-22 Alphavax Alphavirus Replicon Particles Matched to Protein Antigens as Immunological Adjuvants
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
GB0706914D0 (en) 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
CA2687141C (en) 2007-05-22 2014-04-01 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
WO2008145685A1 (en) 2007-05-31 2008-12-04 Genimmune N.V. Hpv polyepitope constructs and uses thereof
US7850977B2 (en) 2007-06-21 2010-12-14 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
US20100015179A1 (en) 2007-08-16 2010-01-21 Frolov Ilya V Attenuation of encephalitogenic alphavirus and uses thereof
US20100286070A1 (en) 2007-09-14 2010-11-11 Gert Verheyden Affinity tag
US20100285050A1 (en) 2007-10-05 2010-11-11 Isis Innovation Limited Compositions and Methods
GB0719526D0 (en) 2007-10-05 2007-11-14 Isis Innovation Compositions and methods
CA2705787A1 (en) 2007-11-26 2009-06-25 Novartis Ag Methods of generating alphavirus particles
US20110091496A1 (en) 2008-01-19 2011-04-21 Graham Barney S Methods and compositions for the delivery of vaccines to disrupted epithelium
US20090253184A1 (en) 2008-01-23 2009-10-08 Introgen Therapeutics, Inc. Compositions and methods related to an adenoviral trans-complementing cell line
NZ587502A (en) 2008-01-24 2012-12-21 Univ Texas Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
CA2719938A1 (en) 2008-03-28 2009-10-01 Virxsys Corporation Lentivirus-based immunogenic vectors
EP2297187A1 (en) 2008-06-03 2011-03-23 Okairos AG A vaccine for the prevention and therapy of hcv infections
WO2010005704A2 (en) 2008-06-13 2010-01-14 New York University Novel helper plasmid, defective sindbis viral vectors and methods of use thereof
EP2310510B1 (en) 2008-07-17 2015-05-06 Medigen, Inc. Idna vaccines and methods for using the same
RS53782B1 (en) 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh TUMOR-ASSOCIATED PEPTIDES PREPARED AND ANTI-CHANGE RESPONSE FOR GLIOBLASTOMA (GBM) AND OTHER CANCER TREATMENTS
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
WO2010044515A1 (en) 2008-10-17 2010-04-22 Lee Jeong-Min Bottle cap
EP3613761A1 (en) 2008-11-26 2020-02-26 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Virus like particle compositions and methods of use
WO2010065414A1 (en) 2008-12-01 2010-06-10 Alphavax, Inc. Use of micrornas to control virus helper nucleic acids
DE102008061522A1 (en) 2008-12-10 2010-06-17 Biontech Ag Use of Flt3 ligand to enhance immune responses in RNA immunization
CA2749325C (en) * 2009-02-02 2021-03-30 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
CN101579528B (en) 2009-06-24 2011-06-29 中国人民解放军军事医学科学院军事兽医研究所 HIV composite multi-epitope DNA vaccine and application thereof
EP2451475A2 (en) 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
GB0918154D0 (en) 2009-10-16 2009-12-02 Isis Innovation Mycobacterial vaccines
EP2519266B1 (en) 2009-12-31 2017-07-26 Medigen, Inc. Infectious dna vaccines against chikungunya virus
GB201006405D0 (en) 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
AU2011252795B2 (en) 2010-05-14 2015-09-03 Dana-Farber Cancer Institute, Inc. Compositions and methods of identifying tumor specific neoantigens
ES2586580T3 (en) 2010-07-06 2016-10-17 Glaxosmithkline Biologicals Sa Immunization of large mammals with low doses of RNA
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
EP2590625B1 (en) 2010-07-06 2017-09-20 GlaxoSmithKline Biologicals SA Cationic oil-in-water emulsions
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
MX342608B (en) 2010-07-06 2016-10-06 Novartis Ag * Virion-like delivery particles for self-replicating rna molecules.
ES2770335T3 (en) 2010-07-06 2020-07-01 Glaxosmithkline Biologicals Sa RNA administration to trigger multiple immune pathways
SI2590626T1 (en) 2010-07-06 2016-01-29 Glaxosmithkline Biologicals S.A. Liposomes with lipids having an advantageous pka-value for rna delivery
CA2807778C (en) 2010-08-16 2017-03-07 Salk Institute For Biological Studies Anti-cancer adenoviruses
PL4043040T3 (en) 2010-08-31 2023-04-17 Glaxosmithkline Biologicals Sa Small liposomes for delivery of immunogen-encoding rna
LT4226941T (en) 2010-08-31 2025-01-10 Glaxosmithkline Biologicals Sa Pegylated liposomes for delivery of immunogen-encoding rna
AU2011295938B2 (en) 2010-08-31 2016-01-14 Glaxosmithkline Biologicals S.A. Lipids suitable for liposomal delivery of protein-coding RNA
JP6054303B2 (en) 2010-12-30 2016-12-27 ファウンデーション メディシン インコーポレイテッドＦｏｕｎｄａｔｉｏｎ Ｍｅｄｉｃｉｎｅ， Ｉｎｃ． Optimization of multigene analysis of tumor samples
WO2012106356A2 (en) 2011-01-31 2012-08-09 GOVERNMENT OF THE USA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES Virus-like particles and methods of use
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
AU2012255971A1 (en) 2011-05-13 2013-05-02 Novartis Ag Pre-fusion RSV F antigens
HRP20250981T1 (en) 2011-05-24 2025-10-24 BioNTech SE Individualized vaccines for cancer
GB201108879D0 (en) 2011-05-25 2011-07-06 Isis Innovation Vector
WO2012171541A1 (en) 2011-06-15 2012-12-20 Scil Proteins Gmbh Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
RU2014104090A (en) 2011-07-06 2015-08-20 Новартис Аг LIPOSOMES WITH AN EFFECTIVE N: P RATIO FOR DELIVERY OF PHK MOLECULES
CA2840989A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
CA2841047A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
EP2559441B1 (en) 2011-08-16 2021-07-21 Samsung Electronics Co., Ltd. Protein complex for intracellular delivery and uses thereof
HRP20190032T1 (en) 2011-08-31 2019-02-22 Glaxosmithkline Biologicals Sa PEGILATED LIPOSOMS, INTENDED FOR RNA IMPROVEMENT, CODING IMMUNOGEN
EP2771349B1 (en) 2011-09-16 2020-02-26 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
BR112014008694A2 (en) 2011-10-11 2017-06-20 Novartis Ag recombinant polycistronic nucleic acid molecules
BR112014020052B8 (en) 2012-02-16 2023-04-18 Vlp Therapeutics Llc VIRUS-TYPE PARTICLE, COMPOSITIONS, ANTIBODY PRODUCTION METHOD AND USE OF SAID PARTICLE
US20160289674A1 (en) 2012-04-02 2016-10-06 Moderna Therapeutics, Inc. Modified polynucleotides for the production of membrane proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
SG11201407343XA (en) 2012-05-18 2014-12-30 Univ Pennsylvania Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
WO2013190090A1 (en) 2012-06-21 2013-12-27 Philip Morris Products S.A. Gene signatures for classifying and grading lung cancer
WO2014006146A1 (en) 2012-07-04 2014-01-09 Sirion Biotech Gmbh Means and methods to increase adenovirus production
EP2869842A1 (en) 2012-07-06 2015-05-13 Novartis AG Immunogenic compositions and uses thereof
US8961995B2 (en) 2012-09-20 2015-02-24 Uab Research Foundation Methods and compositions for alphavirus replicons
GB201220119D0 (en) 2012-11-08 2012-12-26 Univ Cork Vector
EP3564380B1 (en) 2012-11-16 2025-06-18 Beth Israel Deaconess Medical Center, Inc. Recombinant adenoviruses and use thereof
KR101429696B1 (en) 2012-11-21 2014-08-13 국립암센터 Recombinant adenovirus with enhanced safety and anti-cancer activity and use thereof
US9402888B2 (en) 2013-03-14 2016-08-02 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating cancer
KR20210156320A (en) 2013-04-07 2021-12-24 더 브로드 인스티튜트, 인코퍼레이티드 Compositions and methods for personalized neoplasia vaccines
EP3004348B1 (en) 2013-06-03 2023-03-08 VLP Therapeutics, Inc. Malaria vaccine
TWI776192B (en) 2013-08-05 2022-09-01 德商伊瑪提克斯生物科技有限公司 Novel peptides, cells, and their use against several tumors, methods for production thereof and pharmaceutical composition comprising the same
TR201903074T4 (en) 2013-11-01 2019-03-21 Pfizer Vectors for the expression of prostate associated antigens.
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
CN106132432A (en) 2013-12-06 2016-11-16 博德研究所 Preparation for neoplasia vaccine
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
BR112017004202A2 (en) 2014-09-03 2019-09-03 Bavarian Nordic As compositions for enhancing immune responses and their uses
US11085084B2 (en) 2014-09-12 2021-08-10 The Board Of Trustees Of The Leland Stanford Junior University Identification and use of circulating nucleic acids
SG10201913978RA (en) 2014-11-26 2020-03-30 The United States Of America As Represented By The Secretary Anti-mutated kras t cell receptors
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
SG11201706118XA (en) 2015-01-29 2017-08-30 Agency Science Tech & Res Nanocapsules carrying chikungunya-associated peptides
US20180030140A1 (en) 2015-02-06 2018-02-01 Navigo Proteins Gmbh Novel binding proteins comprising a ubiquitin mutein and antibodies or antibody fragments
WO2016154047A2 (en) 2015-03-20 2016-09-29 Memorial Sloan-Kettering Cancer Center Monoclonal antigen-binding proteins to intracellular oncogene products
EP3286222A4 (en) 2015-03-23 2018-08-08 The Johns Hopkins University Hla-restricted epitopes encoded by somatically mutated genes
PE20180670A1 (en) 2015-05-20 2018-04-19 Broad Inst Inc SHARED NEOANTIGENS
DK3954225T5 (en) 2015-09-21 2024-08-05 Trilink Biotechnologies Llc Initiating capped oligonucleotide primers for synthesizing 5' capped RNA
CN115418401A (en) 2015-10-08 2022-12-02 会聚基因学有限公司 Diagnostic assay for urine monitoring of bladder cancer
KR20180083327A (en) 2015-10-12 2018-07-20 난토믹스, 엘엘씨 Composition and method for viral cancer neoepitope
EP4011451A1 (en) 2015-10-22 2022-06-15 ModernaTX, Inc. Metapneumovirus mrna vaccines
RU2729116C2 (en) 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Identification, production and use of neoantigens
KR102358206B1 (en) 2016-02-29 2022-02-04 파운데이션 메디신 인코포레이티드 Methods and systems for assessing tumor mutational burden
AU2017225787B2 (en) 2016-03-03 2021-09-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CR20180519A (en) 2016-03-31 2019-03-05 Neon Therapeutics Inc NEOANT US AND METHODS OF USE
US20190346442A1 (en) 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
CA3022267A1 (en) 2016-05-04 2017-11-09 Fred Hutchinson Cancer Research Center Cell-based neoantigen vaccines and uses thereof
EP3463445A1 (en) 2016-06-02 2019-04-10 GlaxoSmithKline Biologicals SA Zika viral antigen constructs
IL291537B2 (en) 2016-06-20 2023-11-01 Isa Pharmaceuticals B V Formulation of a peptide vaccine
GB2549809C (en) 2016-06-23 2022-11-30 Univ Oxford Innovation Ltd Vector
CN107698593A (en) 2016-08-09 2018-02-16 南京天印健华医药科技有限公司 Heterocyclic compound as FGFR inhibitor
US20210284733A1 (en) 2016-08-22 2021-09-16 Arbutus Biopharma Corporation Anti-pd-1 antibodies, or fragments thereof, for treating hepatitis b
CN110545810A (en) 2016-11-23 2019-12-06 磨石肿瘤生物技术公司 Viral delivery of neoantigens
WO2018102585A1 (en) 2016-11-30 2018-06-07 Advaxis, Inc. Personalized immunotherapy in combination with immunotherapy targeting recurrent cancer mutations
CA3045976A1 (en) 2016-12-09 2018-06-14 Glaxosmithkline Biologicals Sa Chimpanzee adenovirus constructs with lyssavirus antigens
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
GB201621732D0 (en) 2016-12-20 2017-02-01 Agricultural Research Council A multi-epitope dna vaccine for heartwater
CA3047326A1 (en) 2016-12-21 2018-06-28 Arbutus Biopharma Corporation Methods for ameliorating infusion reactions
EP3606550A2 (en) 2017-04-03 2020-02-12 Neon Therapeutics, Inc. Protein antigens and uses thereof
SG11201910101SA (en) 2017-05-08 2019-11-28 Gritstone Oncology Inc Alphavirus neoantigen vectors
AU2018279627B2 (en) 2017-06-09 2023-08-10 Seattle Project Corp. Neoantigen identification, manufacture, and use
TW201919653A (en) 2017-06-16 2019-06-01 加拿大商艾爾布圖斯生技公司 Therapeutic compositions and methods for treating hepatitis B
US11674962B2 (en) 2017-07-21 2023-06-13 Genentech, Inc. Therapeutic and diagnostic methods for cancer
CN111868260B (en) 2017-08-07 2025-02-21 约翰斯霍普金斯大学 Methods and materials for evaluating and treating cancer
EP4549588A3 (en) 2017-11-03 2025-07-23 Guardant Health, Inc. Normalizing tumor mutation burden
US11793867B2 (en) 2017-12-18 2023-10-24 Biontech Us Inc. Neoantigens and uses thereof
CN112020563A (en) 2018-03-06 2020-12-01 癌症研究技术有限公司 Improvements to variant detection
WO2019200228A1 (en) 2018-04-14 2019-10-17 Natera, Inc. Methods for cancer detection and monitoring by means of personalized detection of circulating tumor dna
TW202000907A (en) 2018-05-23 2020-01-01 美商葛利史東腫瘤科技公司 Shared antigens
WO2019226939A1 (en) 2018-05-23 2019-11-28 Gritstone Oncology, Inc. Immune checkpoint inhibitor co-expression vectors
JP2022512912A (en) 2018-11-07 2022-02-07 グリットストーン バイオ インコーポレイテッド Alpha virus nascent antigen vector and interferon inhibitor
BR112021024127A2 (en) * 2019-05-30 2022-04-26 Gritstone Bio Inc modified adenovirus
WO2021003348A1 (en) 2019-07-02 2021-01-07 Gritstone Oncology, Inc. Hiv antigens and mhc complexes
WO2021092095A1 (en) 2019-11-04 2021-05-14 Gritstone Oncology, Inc. Neoantigen vaccine therapy
WO2021119545A1 (en) 2019-12-11 2021-06-17 Gritstone Bio, Inc. Durable vaccination
WO2021142437A1 (en) 2020-01-10 2021-07-15 Gritstone Bio, Inc. Cell-free dna monitoring
IL296854A (en) 2020-04-21 2022-11-01 Gritstone Bio Inc Cassettes for antigen coding
WO2022032196A2 (en) 2020-08-06 2022-02-10 Gritstone Bio, Inc. Multiepitope vaccine cassettes

Also Published As

Publication number Publication date
US20240024445A1 (en) 2024-01-25
US20250249084A1 (en) 2025-08-07
KR20200003390A (en) 2020-01-09
CO2019013609A2 (en) 2020-04-01
US20200197500A1 (en) 2020-06-25
EP3634449A1 (en) 2020-04-15
IL270396B1 (en) 2024-10-01
TW201907937A (en) 2019-03-01
IL315224A (en) 2024-10-01
TW202333779A (en) 2023-09-01
AU2018266705A1 (en) 2020-01-02
PE20191842A1 (en) 2019-12-31
CA3062591A1 (en) 2018-11-15
US11504421B2 (en) 2022-11-22
AU2023202423A1 (en) 2023-05-11
AU2018266705B2 (en) 2023-05-04
US20220226453A1 (en) 2022-07-21
EP3634449A4 (en) 2021-03-17
US11510973B2 (en) 2022-11-29
JP2020518648A (en) 2020-06-25
PH12019502518A1 (en) 2020-07-20
IL270396A (en) 2019-12-31
ZA201907461B (en) 2023-04-26
WO2018208856A1 (en) 2018-11-15
CN110612116A (en) 2019-12-24
IL270396B2 (en) 2025-02-01
RU2019138741A (en) 2021-06-09
RU2019138741A3 (en) 2021-09-23
MX2025009055A (en) 2025-09-02
MX2019013259A (en) 2020-01-13
AU2023202423B2 (en) 2025-11-27
BR112019023477A2 (en) 2020-06-30
US12109257B2 (en) 2024-10-08
JP2023123766A (en) 2023-09-05

Similar Documents

Publication Publication Date Title
SG11201910101SA (en) Alphavirus neoantigen vectors
SG11201909652WA (en) Neoantigen identification, manufacture, and use
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201804957VA (en) Neoantigen identification, manufacture, and use
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201810465RA (en) Compositions and methods related to engineered fc constructs
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201807538PA (en) Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201804384UA (en) Geometric configurations for gastric residence systems
SG11201806630QA (en) Self-propelled personal transportation device
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201407579QA (en) Interleukin-2 fusion proteins and uses thereof
SG11201807025SA (en) Crispr/cas systems for c-1 fixing bacteria
SG11201908675PA (en) Computer-implemented system and method for performing transaction mixing on a blockchain
SG11201908075UA (en) A microneedle device
SG11201809751XA (en) Egfr inhibitor compounds
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201900200XA (en) Tgfb antibodies, methods, and uses
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201811550XA (en) Demand prediction for time-expiring inventory
SG11201805381TA (en) Electroporation device with detachable needle array with lock-out system
SG11201902745RA (en) Optimizing training sets used for setting up inspection-related algorithms